GHRL and obesity due to melanocortin 4 receptor deficiency: Ghrelin receptor antagonists, GSH-R1demonstrated improved glucose tolerance, suppressed appetite and promoted weight loss [13], thus confirming the potential of ghrelin blocking as a potential treatment target for obesity.